SCHEMBL10051189

SCHEMBL10051189

N#Cc1ccc(-c2ccc(-c3ccc(-c4ccc(-c5cccc6ccccc56)cc4)c4ccccc34)c3ccccc23)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.49
CYP2C9 P11712 1/20 0.49
CYP2C19 P33261 1/20 0.49
MCL1 Q07820 1/20 0.47
CA1 P00915 5/20 0.46
CA2 P00918 5/20 0.46
CA12 O43570 3/20 0.46
CA9 Q16790 3/20 0.46
PIM1 P11309 2/20 0.46
HDAC8 Q9BY41 1/20 0.45
HDAC6 Q9UBN7 1/20 0.45
ENPP3 O14638 1/20 0.43
ENPP1 P22413 1/20 0.43
IRAK4 Q9NWZ3 1/20 0.42
IDO1 P14902 1/20 0.42
ALOX15 P16050 1/20 0.42
CHRNB4 P30926 1/20 0.41
CHRNA3 P32297 1/20 0.41
CHRNA7 P36544 1/20 0.41
TNF P01375 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26750958 1.00 CYP1A2 (0.49) CYP1A2CYP2C9CYP2C19MCL1CA1
SCHEMBL10296082 0.96 CYP1A2 (0.51) CYP1A2CYP2C9CYP2C19MCL1CA1
SCHEMBL22360100 0.95 CA1 (0.51) CYP1A2CYP2C9CYP2C19MCL1CA1
SCHEMBL26750844 0.92 CYP1A2 (0.46) CYP1A2CYP2C9CYP2C19MCL1CA1
SCHEMBL15077954 0.91 PIM1 (0.43) CYP1A2CYP2C9CYP2C19MCL1CA1
SCHEMBL13170784 0.90 CYP1A2 (0.47) CYP1A2CYP2C9CYP2C19MCL1CA1
SCHEMBL10051153 0.88 MCL1 (0.47) CYP1A2CYP2C9CYP2C19MCL1CA1
SCHEMBL13170797 0.88 CA1 (0.46) CYP1A2CYP2C9CYP2C19MCL1CA1
SCHEMBL13192342 0.88 PIM1 (0.40) CYP1A2CYP2C9CYP2C19MCL1CA1
SCHEMBL10051180 0.87 ADRA2C (0.49) CYP1A2CYP2C9CYP2C19MCL1CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2015089028-A1 PHOTOACTIVE COMPOSITIONS FOR ELECTRONIC APPLICATIONS E. I. DU PONT DE NEMOURS AND COMPANY (US) 2015-06-18 WO disclosed
US-20120187383-A1 ELECTROACTIVE COMPOUND AND COMPOSITION AND ELECTRONIC DEVICE MADE WITH THE COMPOSITION E.I. DU PONT DE NEMOURS AND COMPANY (US) 2012-07-26 US disclosed
US-20120187383-A1 ELECTROACTIVE COMPOUND AND COMPOSITION AND ELECTRONIC DEVICE MADE WITH THE COMPOSITION E.I. DU PONT DE NEMOURS AND COMPANY (US) 2012-07-26 US disclosed
WO-2012021315-A2 ELECTROACTIVE COMPOUND AND COMPOSITION AND ELECTRONIC DEVICE MADE WITH THE COMPOSITION E. I. DU PONT DE NEMOURS AND COMPANY (US) 2012-02-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120187383-A1 ELECTROACTIVE COMPOUND AND COMPOSITION AND ELECTRONIC DEVICE MADE WITH THE COMPOSITION CCNL2, ESR1, ESR2 CYP1A2 475/4885CYP2C9 927/4885CYP2C19 864/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.